{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"45.4","value":"14.5"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"13.4","value":"6.8"},{"groupId":"OG002","lowerLimit":"3.8","upperLimit":"12.2","value":"5.2"},{"groupId":"OG003","lowerLimit":"8.1","upperLimit":"72.9","value":"26.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"description":"Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. PD: \\>=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.","dispersionType":"Full Range","groups":[{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).","id":"OG000","title":"RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).","id":"OG001","title":"RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).","id":"OG002","title":"RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).","id":"OG003","title":"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, \"Overall number of participants analyzed\" signifies number of participants who were objective responders. Data was planned to be analyzed for reported arms only.","reportingStatus":"POSTED","timeFrame":"From first documentation of response to date of PD or death due to any cause (up to 172 months)","title":"Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)","type":"PRIMARY","unitOfMeasure":"Weeks"}